Hypomethylating Agent 5‐Aza‐2′‐deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models
Katia Mangano(University of Catania), Ferdinando Nicoletti(University of Catania), Paolo Fagone(University of Catania), Michelino Di Rosa(St Bartholomew's Hospital), Pier Luigi Meroni(IRCCS Istituto Auxologico Italiano), Santa Mammana(University of Catania), Gaetano Magro(University of Catania), Lucia Malaguarnera(University of Catania), Cinzia Quattrocchi, Roberto Di Marco(University of Catania), Klaus Bendtzen(Rigshospitalet), Marinella Coco(University of Catania)
Cited by 58
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508